Get the Stockscreener App
1.00
3.85%
-0.04
After Hours:
1.03
0.03
+3.00%
Tenaya Therapeutics Inc stock is traded at $1.00, with a volume of 3.05M.
It is down -3.85% in the last 24 hours and down -34.21% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
See More
Previous Close:
$1.04
Open:
$1.05
24h Volume:
3.05M
Relative Volume:
0.62
Market Cap:
$79.22M
Revenue:
-
Net Income/Loss:
$-117.23M
P/E Ratio:
-0.6944
EPS:
-1.44
Net Cash Flow:
$-95.25M
1W Performance:
-5.66%
1M Performance:
-34.21%
6M Performance:
-62.96%
1Y Performance:
-78.12%
1-Day Range:
$1.00
$1.075
1-Week Range:
$1.00
$1.1199
52-Week Range:
$0.9867
$7.01
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
1.00 | 79.22M | 0 | -117.23M | -95.25M | -1.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
BlackRock, Inc. Acquires Additional Shares in Tenaya Therapeutics Inc - GuruFocus.com
A History of Outperforming Analyst Forecasts and Beating the Odds: Tenaya Therapeutics Inc (TNYA) - SETE News
Recent Insider Activity Suggests Potential Gains for Tenaya Therapeutics Inc (TNYA) - Knox Daily
Tenaya Therapeutics (NASDAQ:TNYA) Earns “Buy” Rating from HC Wainwright - Defense World
Analyze Tenaya Therapeutics Inc (NASDAQ: TNYA) Before Investing. - Stocks Register
Market Watch Highlights: Tenaya Therapeutics Inc (TNYA) Ends on an Downturn Note at 1.05 - The Dwinnex
H.C. Wainwright maintains buy rating on Tenaya Therapeutics stock - Investing.com
Is Tenaya Therapeutics Inc (TNYA) a good investment opportunity? - US Post News
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine - GlobeNewswire
TNYATenaya Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Tenaya Therapeutics receives $8M clinical grant from CIRM - MSN
HC Wainwright Reiterates "Buy" Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Promising Potential of Tenaya Therapeutics: Buy Rating Justified by Financial Backing and Clinical Progress - TipRanks
Major Funding Breakthrough: Rare Heart Disease Gene Therapy Trial Gets $8M Boost - StockTitan
Tenaya Therapeutics announces option repricing to retain staff By Investing.com - Investing.com Australia
Tenaya Therapeutics announces option repricing to retain staff - Investing.com
Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely - Simply Wall St
Tenaya Therapeutics (TNYA) Stock Price, News & Analysis - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by Jane Street Group LLC - Defense World
Jane Street Group LLC Sells 89,680 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Brokerages - MarketBeat
Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) PT at $17.33 - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Update - MarketBeat
HC Wainwright Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya advances gene therapies for heart conditions By Investing.com - Investing.com Canada
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - GlobeNewswire
Tenaya advances gene therapies for heart conditions - Investing.com
Tenaya Therapeutics Advances Gene Therapy Programs with Promising TN-201 Trial Progress - StockTitan
Analysts Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $17.33 - MarketBeat
Geode Capital Management LLC Increases Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Things To Consider Before Buying Tenaya Therapeutics Inc (NASDAQ: TNYA) - Stocks Register
Zhongzhi drops $3M in Gabaeron series A for stem cell AD therapy - BioWorld Online
Largest borrow rate increases among liquid names - TipRanks
State Street Corp Purchases 9,506 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease (TNYA) - Seeking Alpha
Short Interest in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Grows By 18.8% - MarketBeat
Reviewing Caribou Biosciences (NASDAQ:CRBU) & Tenaya Therapeutics (NASDAQ:TNYA) - Defense World
XTX Topco Ltd Has $95,000 Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Earns Buy Rating from Chardan Capital - Defense World
Tenaya Therapeutics (NASDAQ: TNYA) Senior Vice President Chihiro Saito Resigns: 8-K Filing - Defense World
Tenaya Therapeutics stock backed by H.C. Wainwright on TN-401 safety and protein expression gains - Investing.com
Tenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from Chardan Capital - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Given "Buy" Rating at HC Wainwright - MarketBeat
Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data - BioSpace
Tenaya Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):